文献速递骨软组织肉瘤与黑色素瘤

转录组可塑性与空间结构塑造黑色素瘤免疫治疗及联合BRAF/MEK抑制的应答

Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi.
PubMed 文献 · J Clin Oncol · 2026-09-22

本研究整合IMspire150、BRIM、AVAST-M及公开免疫治疗黑色素瘤队列的临床与多组学数据,识别与ICB及BRAF/MEK抑制联合ICB应答或耐药相关的转录状态。发现两种主要ICB耐药状态:分化型与未分化型,分化型肿瘤在BRAF/MEK抑制联合ICB下结局改善,而未分化型对ICB及MAPK联合应答均较差且富集血管生成与基质程序。结论支持基于生物标志物选择患者,对分化型考虑联合MAPK抑制而非单用ICB。

要点

  • 分化型黑色素瘤单用ICB获益有限,但联合BRAF/MEK抑制后结局改善。
  • 未分化型对ICB及MAPK联合应答均差,富集血管生成与基质程序。
  • 未分化型在回顾性分析中抗VEGF治疗结局改善,临床前对CDK7抑制敏感。

核心结论

  • 建立转录分类框架,定义对ICB及联合MAPK靶向治疗应答或耐药的不同生物学亚组。

研究设计与样本

  • 整合IMspire150、BRIM、AVAST-M及公开免疫治疗黑色素瘤队列的临床与多组学数据。
  • 采用功能实验与空间转录组分析验证与BRAF/MEK抑制联合ICB应答或耐药相关的机制假设。

主要发现

  • 识别两种主要ICB耐药状态:分化型与未分化型,具有不同临床与微环境特征。
  • 分化型肿瘤在BRAF/MEK抑制联合ICB下结局改善,尽管单用ICB获益有限。
  • 未分化型对ICB及MAPK靶向联合应答均较差,富集血管生成与基质程序。
  • 未分化型在回顾性分析中抗VEGF治疗结局改善,临床前模型对CDK7抑制敏感。

临床怎么用

  • 支持基于生物标志物识别可从ICB联合MAPK抑制(而非单用ICB)中获益的患者。
  • 未分化型患者可能需考虑抗血管生成或CDK7抑制等替代策略,但仍需前瞻验证。

局限性

  • 部分证据来自回顾性分析及临床前模型,需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In BRAF-mutant melanoma, clinical trials evaluating combination and sequencing strategies of MAPK-targeted therapy with immune checkpoint blockade (ICB) have yielded mixed results. We sought to define tumor biology associated with resistance to ICB and response to ICB and its combination with MAPK-targeted therapy, and determine biomarkers to guide treatment strategies. PATIENTS AND METHODS: We integrated clinical with multi-omics data from IMspire150, BRIM, AVAST-M, and publicly available immunotherapy-treated melanoma cohorts to identify transcriptional states associated with response or resistance to ICB and BRAF/MEK inhibition combined with ICB. Functional assays and spatial transcriptomic analyses were used to evaluate and validate the underlying mechanistic hypothesis associated with response or resistance to BRAF/MEK inhibition combined with ICB. RESULTS: Two major ICB-resistant states were identified: differentiated and undifferentiated tumors with distinct clinical and microenvironmental features. Differentiated tumors were associated with improved outcomes with BRAF/MEK inhibition combined with ICB, despite limited benefit from ICB alone. In contrast, undifferentiated tumors were less responsive to both ICB and MAPK-targeted combinations and were enriched for angiogenic and stromal programs. These tumors were associated with improved outcomes following anti-vascular endothelial growth factor therapy in retrospective analyses and showed sensitivity to CDK7 inhibition in preclinical models. CONCLUSION: Using the largest melanoma clinical-molecular data set, we have defined a transcriptional classification framework that defines biologically distinct patient subgroups associated with response or resistance to ICB and its combination with MAPK-targeted therapies. These findings support biomarker-driven approaches to identify patients who may benefit from therapeutic escalation by adding MAPK inhibition to ICB rather than ICB alone, as well as a subgroup with persistent unmet need.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shah K, Nguyen DAH, Gold M, et al. Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi. J Clin Oncol. 2026. PMID: 42771837. doi:10.1200/JCO-25-02766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。